Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Prior treatment

• Greater than Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at the time of inclusion
• Subject receiving an immunosuppressive treatment for GVHD treatment due to a previous allograft at the time of inclusion
• Serious concurrent uncontrolled medical disorder
• For subjects who have received more than 1 x 10E5 alpha/beta T cells/kg with the graft infusion the clinical trial site must contact the sponsor for approval to be eligible to receive BPX-501 infusion.

Other illness

• Current active infectious disease (including positive HIV serology or viral RNA)

Lab values

• Dysfunction of liver (ALT/AST \> 5 times normal value, or bilirubin \> 3 times normal value), or of renal function (creatinine clearance \< 30 mL / min)
• Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction \< 40%)

Other

• Pregnant or breastfeeding subject

• Age \> 1 month and \< 26 years
• Life expectancy \> 10 weeks
• Subjects deemed eligible for allogeneic stem cell transplantation.
• Subjects with life-threatening hematological malignancies (high-risk ALL in 1st CR, ALL in 2nd or subsequent CR, AML in 1st CR, AML in 2nd or subsequent CR, myelodysplastic syndromes, non-Hodgkin lymphomas in 2nd or subsequent CR, other hematologic malignancies eligible for stem cell transplantation per institutional standard);
• Non-malignant disorders amenable to cure by an allograft:
  • primary immune deficiencies,
  • severe aplastic anemia not responding to immune suppressive therapy,
  • osteopetrosis,
  • hemoglobinopathies, (thalassemias, and sickle cell anemia, and Diamond-Blackfan anemia among others)
  • congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML) Note: Subjects will be eligible if they meet either item 4 OR item 5.
• Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor
• A minimum genotypic identical match of 5/ 10 is required.
• The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
• Lansky/Karnofsky score \> 50
• Signed written informed consent